Latest Updates
Read the latest news that impacts the oncology community.
340B incentivizes hospital-clinic M&A, drives higher health spending: CBO
The 340B program requires drugmakers to sell outpatient drugs to safety-net hospitals and clinics at a significant discount.
Read MoreCarter, Harshbarger Introduce Legislation to Ensure Access and Transparency in 340B Drug Pricing Program
WASHINGTON, D.C. – Rep. Earl L. “Buddy” Carter (R-GA) and Diana Harshbarger (R-TN) today introduced the 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act).
Read MoreHospital mergers harm rural health outcomes
The hospital industry is one of the most important sections in the U.S. economy, both due to its size (accounting for nearly $1.3 trillion in spending) and its impact on the health and wellbeing of the general population.
Read MorePa. pharmacists say more reform is needed to stem closures
On Wednesday, a bipartisan group of state senators heard from pharmacy owners about the impacts of pharmacy benefit manager reforms and what can still be done to stop pharmacies across the commonwealth from closing.
Read MoreCBO: 340B program costs taxpayers, no evidence patients benefit
Taxpayers pay, hospitals play. The non-partisan Congressional Budget Office (CBO) confirms the 340B hospital markup program is costing taxpayers money.
Read MoreCBO Releases Major Report on 340B
The Congressional Budget Office published its investigation into 340B, finding in part that “the 340B program encourages behaviors—including the prescription of more and higher-priced drugs, the expansion of services, and the integration of hospitals and off-site clinics—that tend to increase federal spending.” Read the report here.
Read MoreCBO Confirms 340B Drug Pricing Program Increases Costs for Federal Taxpayers
WASHINGTON, D.C. – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, issued the following statement in response to the Congressional Budget Office’s (CBO) report released September 9th, which confirmed the 340B Drug Pricing Program encourages behaviors that increase federal spending and raise prices for American taxpayers. Some of those behaviors include incentivizing the prescription of more expensive drugs, reducing negotiated rebates for insurers, and increasing vertical integration among facilities.
Read MoreSpending on 340B drug program rose to $43.9B in 2021, CBO says
Over a little more than a decade, spending on the federal 340B drug program rose to $43.9 billion in 2021, according to a new report from the Congressional Budget Office.
Read More340B drug spending rose 565% from 2010-2021, CBO reports
Spending on prescription medications under the 340B Drug Pricing Program grew more than sixfold from 2010 to 2021, according to a report the nonpartisan Congressional Budget Office published Tuesday.
Read MoreHouse Republicans probe CVS for alleged HIPAA violation
The letter stems from reports that on June 11 CVS sent a mass text message to thousands of customers in Louisiana using data that patients shared with the company for prescription drug services.
Read More